Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

  1. Giovannoni, G.
  2. Barbarash, O.
  3. Casset-Semanaz, F.
  4. King, J.
  5. Metz, L.
  6. Pardo, G.
  7. Simsarian, J.
  8. Sørensen, P.S.
  9. Stubinski, B.
  10. Carra, A.
  11. Cristiano, E.
  12. Luetic, G.
  13. Rodriguez Alfici, A.
  14. Cruz, G.
  15. Vetere, S.
  16. Pollard, J.
  17. Boundy, K.
  18. Sedal, L.
  19. Butzkueven, H.
  20. MacDonnell, R.
  21. Zabad, R.K.
  22. Soelberg Sørensen, P.
  23. Hardiman, O.
  24. Tubridy, N.
  25. Karussis, D.
  26. Achiron, A.
  27. Vaitkus, A.
  28. Kizlaitiene, R.
  29. Lesnyak, O.
  30. Zaslavsky, L.
  31. Poverennova, I.
  32. Sidorov, P.
  33. Khasanova, D.
  34. Alifirova, V.
  35. Casanova, B.
  36. Balyazin, V.
  37. Lutsky, M.
  38. Rodríguez-Antigüedad, A.
  39. García-Merino, J.
  40. Arroyo, R.
  41. Olsson, T.
  42. Barnes, D.
  43. Young, C.
  44. O'Riordan, J.
  45. Malik, O.
  46. Armstrong, R.
  47. Sheppard, C.
  48. Thrower, B.
  49. Wray, S.
  50. Gross, J.
  51. Wynn, D.
  52. Miller, T.
  53. Garmany, G.
  54. Sherman, M.
  55. Show all authors +
Journal:
Multiple Sclerosis

ISSN: 1352-4585

Year of publication: 2009

Volume: 15

Issue: 2

Pages: 219-228

Type: Article

DOI: 10.1177/1352458508097299 GOOGLE SCHOLAR

Sustainable development goals